PUBLICATIONS

REFEREED JOURNAL MANUSCRIPTS

1. Chrzanowski FA, Ahmad K. The Preparation and Evaluation of Salt Forms of Linogliride with Reduced Solubilities as Candidates for Controlled Release. Drug Dev and Ind Pharm (IDDI) 2016;32:1-37. Epub 216 Nov 3. doi:10.1080/03639045.2016.1257019.
2. Chrzanowski FA, Evans L, Nguyen M, Fegely B, Koch T. The Vapor Pressure of Topiramate, naphthalene and benzoic acid. IJABPT Jan-Mar, 7(1):267-274.
3. Chrzanowski FA. Preformulation Considerations for Controlled Release Dosage Forms. Part I: Selecting Candidates. AAPS PharmSciTech 2008 June; 9(2):635-8. Epub 2008 Mar 28 doi: 10.1208/s12249-008-9068-2.
4. Chrzanowski FA. Preformulation Considerations for Controlled Release Dosage Forms. Part II: Selected Candidate Support. AAPS PharmSciTech 2008 June;9(2):639-45. Epub 2008 Mar 29 doi: 10.1208/s12249-008-9067-3.
5. Chrzanowski FA. Preformulation Considerations for Controlled Release Dosage Forms. Part III Candidate Form Selection Using Numerical Weighting and Scoring. AAPS PharmSciTech 2008 June; 9(2): 646–650. Epub 2008 May 24. doi: 10.1208/s12249-008-9069-1.
6. Chrzanowski FA, Ulissi LA. The pKa of Cetiedil. Acta Pharm Technol 1987;33:35-37.
7. Chrzanowski FA, Kolod IM, Ahlswede BA, Fegely BJ. A Method for Evaluating the Corrosion Potential of a Tablet Press Turret by Drug Substances, Granulations, and Powder Blends. Drug Dev and Ind Pharm 1986;12:2381-2385.
8. Walkling WD, Sisco WR, Newton MP, Fegely BJ, Chrzanowski FA. Stability of Fenretinide Polymorphs. Acta Pharm Technol 1986;32:10-12.
9. Chrzanowski FA, Ulissi LA, Fegely BJ, Newman AC. Preformulation Excipient Compatibility Testing. Application of a Differential Scanning Calorimetric Method versus a Wet Granulation Simulating, Isothermal Stress Method. Drug Dev and Ind Pharm 1986;12:783-800.
10. Radd BL, Newman AC, Fegely BJ, Chrzanowski FA, Lichtin JL, Walkling WD. Development of Haloperidol in oil Formulation. J Parent Sci and Tech 1985; 38:48-51.
11. Chrzanowski FA, McGrogan BA, Maryanoff BE. The pKa of Butaclamol and the Mode of Butaclamol Binding to Central Dopamine Receptors. J Med Chem 1985;28:399-400.
12. Chrzanowski FA, Fegely BJ, Sisco WR, Newton MP. Analysis of N-(4-hydroxyphenyl)retinamide Polymorphic Forms by X-ray Powder Diffraction. J Pharm Sci 1984;73:1448-1450.
13. Walkling WD, Chrzanowski FA, Egan RS, Ko CY, Paragamian V, Mills JE, Plampin JN. Fenoctimine Sulfate Hydration. Drug Devel and Ind Pharm 1984;10:241-258.
14. Walkling WD, Chrzanowski FA, Mamajek RC, Fegely BJ, Mobley NE, Ulissi LA. Solubilization of Zomepirac. J Parent Sci and Tech 1982;36:190-192.
15. Chrzanowski FA, Niebergall PJ, Mayock RL, Taubin JM. Kinetics of Intravenous Theophylline. Clin Pharmacol Ther 1977;22:188-195.
16. Chrzanowski FA, Niebergall PJ, Mayock RL, Taubin JM, Sugita ET. Interference by Butyl Rubber Stoppers in GLC Analysis for Theophylline. J Pharm Sci 1976;65:735-736.
17. Chrzanowski FA, Niebergall PJ, Nikelly JG, Sugita ET, Schnaare RL. Gas Chromatographic Analysis of Theophylline in Human Serum. Biochem Med 1974;11:26-31.

MEETING ABSTRACTS

1. Chrzanowski FA; Ahmad K, Lichtin JL, Sakr A. Preparation and Evaluation of Salt Forms with Reduced Solubilities as Potential Candidate Forms for Controlled Release. American Association of Pharmaceutical Scientists Annual Meeting; 2007 Nov., San Diego (CA).
2. Chrzanowski FA, Fegely BJ. A Systematic Logical Preformulation Method for Selection of NCE Salt Form for Development. American Association of Pharmaceutical Scientists Annual Meeting; 2001 Oct., Denver (CO).
3. Chrzanowski FA, Koch TA, Evans L, Fegely BJ. Application of Decision Analysis and Potential Problem Analysis to Salt Form Selection. American Association of Pharmaceutical Scientists; 2001 Oct., Denver (CO).
4. Chrzanowski FA, Evans LA, Nguyen MA, Fegely BJ, Koch TS. Determination of the Vapor Pressure of Topiramate Drug Substance. American Association of Pharmaceutical Scientists Annual Meeting; 1994 Nov, San Diego (CA).
5. Chrzanowski FA, Willard R, Fegely BJ, Ahlswede BA, Motto MG, Cotter Ml. Solution Kinetics of Perindopril Erbumine. American Association of Pharmaceutical Scientists Annual Meeting; 1991 Nov, Washington (DC).
6. Ahmad K, Chrzanowski FA, Sakr A, Lichtin JL. Preparation and Evaluation of Linogliride Salts with Reduced Solubilities for Oral Controlled Release. American Association of Pharmaceutical Scientists Inaugural Eastern Regional Meeting; 1987 Sept, Atlantic City (NJ).
7. Chrzanowski FA, Ulissi LA. The pKa of Cetiedil a Sparingly Soluble, Weekly Chromophoric Base. American Association of Pharmaceutical Scientists Annual Meeting; 1986 Nov, Washington (DC).
8. Chrzanowski FA, Kolod IM, Ahlswede BA, Fegely BJ, Urbach JJ. A Method for Evaluating the Corrosion Potential of a Tablet Press Turret by Drug Substances, Granulations or Powder Blends. American Association of Pharmaceutical Scientists Annual Meeting; 1986 Nov, Washington (DC).
9. Walkling WD, Sisco WR, Newton MP, Fegely BJ, Chrzanowski FA. Stability of Fenretinide Polymorphs. APhA Academy of Pharmaceutical Sciences Annual Meeting; 1985 Oct, Minneapolis (MN).
10. Chrzanowski FA, Fegely BJ, Ulissi LA, Newman AC. Preformulation Excipient Compatibility Testing. Application of a Differential Scanning Calorimetric Method versus a Wet Granulation Simulating, Isothermal Stress Method. APhA Academy of Pharmaceutical Sciences Annual Meeting; 1985 Oct, Minneapolis (MN).
11. Chrzanowski FA, Ulissi LA. Kinetics of Cetiedil Hydrolysis. APhA Academy of Pharmaceutical Sciences Annual Meeting; 1984, Philadelphia (PA)
12. Chrzanowski FA, Fegely BJ, Sisco WR, Newton MP. Analysis of N-(4-Hydroxyphenyl)retinamide Polymorphic Forms by X-ray Diffraction. APhA Academy of Pharmaceutical Sciences Annual Meeting; 1983, New Orleans (LA).

INVITED SYMPOSIA, SEMINARS AND TRAINING COURSES

1. Fenoctimine Sulfate Hydration, Issues Involving Hydrate and Anhydrate Differences.​​​​​​​​​
   • Seminar (ZOOM) University of Florida, Graduate Pharmaceutics Dept, 2020, Oct,
2. Preformulation: Quality by Design (QbD) Applied to Salt Form Selection.​​
   • Seminar University of Florida Graduate Pharmaceutics Dept. 2018. Gainesville (FL).​
3. ​The Vapor Pressure of Topiramate. An Environmental Assessment Requirement.​​​​ ​
   • Seminar University of Florida, Graduate Pharmaceutics Dept, 2017 Oct, Gainesville (FL).
4. The Preparation and Characterization of Poorly Soluble Linogliride Salts as Candidates for Extended Release Dosage Form Development.
   • Seminar University of Florida, Graduate Pharmaceutics Dept, 2016 Sept, Gainesville (FL).​
5. Development of HALDOL® Haloperidol Line Extensions.​
   • Seminar University of Florida, Graduate Pharmaceutics Dept, 2015 Oct, Gainesville (FL).​
6. Preformulation Characterization of Candidate Salt Forms and Identification of Optimal Development Forms by Logical and Numerical Scoring / Weighting Methods.
   • Seminar University of Florida, Graduate Pharmaceutics Dept, 2014 Oct, Gainesville (FL).​​
7. Problem Solving, by Solving Problems or In Pharmaceuticals, Sometimes Problem Solving Means Solving Problems.​
   • Seminar University of Florida, Graduate Pharmaceutics Dept, 2013 Sept, Gainesville (FL).
   • Seminar Jacksonville University, Science and Engineering Lecture Series, 2014 Mar, Jacksonville (FL).
8. Resolving Preformulation Problems Related to Polymorphism.​
   • Seminar University of Florida, Graduate Pharmaceutics Dept, 2012 Oct, Gainesville (FL).
9. Facilitating Small Molecule Dosage Form Development Using Solubility Adjustment.​
   • Seminar University of Florida, Graduate Pharmaceutics Dept, 2012 Jan, Gainesville, (FL).​
10. Pharmaceutics 101: Determining the Physical-Chemical properties of an NCE and Resolving Problems in Supporting Dosage Form Development.
    • Seminar University of Northern Florida, Chemistry Dept, 2011 Sept, Jacksonville, (FL).​
11. Preformulation Considerations for Dosage Form Development.​
    • Visiting Scientist Seminar University of Florida, Graduate Pharmaceutics Dept, 2009 Oct, Gainesville (FL).
    • Seminar University of Central Florida, Chemistry Dept, 2015 Oct, Orlando (FL).
12. ​​Preformulation Considerations for Controlled Release Drugs Including Selecting Candidates.​
    • 41st Annual Pharmaceutical Technologies Arden Conference – Oral Controlled Release Development and Technology, American Association of Pharmaceutical Scientists, Pharmaceutical Technology Section, 2006 Jan, West Point (NY).​
13. How to Contract Effectively with Clients.​
    • Round Table American Association of Pharmaceutical Scientists, Annual Meeting, 2005 Nov, Nashville (TN).​
14. Preformulation Characterization of Drug Substances for Dosage Form Development.​​
    • Training Module in Formulation & Process Development for Oral Solid Dosage Forms, PTI-International, 2004 April, Princeton (NJ).​
15. Complying with GMPs for Clinical Manufacturing.​
    • ​Training Course, Pharmaceutical Institute, Presentations in:
      • 2002 Washington (DC), Raleigh (NC);
16. Preformulation Characterization of a Poorly Soluble Retinide.​
    • Symposium American Association of Pharmaceutical Scientists, Annual Eastern Regional Meeting, 1996 Jun, New Brunswick (NJ);
    • Seminar University of Florida, Graduate Pharmaceutics Dept, 2019 Oct, Gainesville (FL).​
17. Application of Crystallographic Data to the Manufacture of Drug Substance and Drug Product..
    • Symposium, American Crystallographic Association, Annual Meeting, 1995 Jul, Montreal (Canada).​
18. Non-Classical Approach to Preformulation.​
    • Workshop 29th Annual Arden House Conference, American Association of Pharmaceutical Scientists, Pharmaceutical Technologies Section, 1994 Jan, Harriman (NY).​
19. Practical Aspects of Physical Characterization Techniques. ​
    • Symposium University of Wisconsin, 35th Annual International Industrial Pharmaceutical Research Conference (Land-O-Lakes), 1993 Jun, Merrimac (WI).​
20. Preformulation Characterization of Drug Substance Forms for Parenteral Product Development.​
    • Symposium Parenteral Drug Association, Annual Meeting and Exhibition, 1992 Mar, Philadelphia (PA).​
21. Preformulation Studies in Pharmaceutical Development.​
    • Lecture Temple University, College of Pharmacy, Industrial Pharmacy Elective Course, (annually) 1989 - 1994, Philadelphia (PA);.
    • AAPS Visiting Scientist Lecture Creighton University College of Pharmacy, 1995 Mar, Omaha (NE).​
22. Preformulation Characterization of Solid-State Drug Substance Forms for Drug Product Development.​
    • Symposium INTERPHEX, Annual Spring Conference, 1989 Apr, New York (NY).​
23. Preformulation Excipient Compatibility Testing.​
    • Seminar University of Cincinnati, 1986 Apr, Cincinnati (OH);
    • AAPS Visiting Scientist Lecture Creighton University College of Pharmacy, 1995 Mar, Omaha (NE).​
24. The Automated Pharmaceutical Development Laboratory.​
    • Symposium 25th Annual Eastern Regional Industrial Pharmaceutical Technology Meeting, 1985 Nov, King of Prussia (PA).​
25. X-ray Diffraction as a Product Development Tool.​
    • Seminar, North Jersey Pharmaceutical Research Discussion Group, 1984 Feb, Mountainside (NJ);
    • Seminar Rutgers University, College of Pharmacy, 1984 Mar, New Brunswick (NJ).
26. Qualitative and Quantitative X-ray Diffraction.​
    • Seminar, Philadelphia College of Pharmacy and Science, Pharmaceutics Dept, 1983 Mar, Philadelphia (PA).​

TECHNICAL MAGAZINE ARTICLES

1. Chrzanowski, FA. Expert Witnesses: Some Good News and Some Bad News. Contract Pharma Expert Opinions (online). April 28 2010.
2. Chrzanowski, FA. How Long Before We Run Out of Ideas? Contract Pharma Expert Opinions (online). March 22 2010.
3. Chrzanowski, FA. Preformulation: More of the Same - An Industry Veteran Explores the History of Preformulation. Contract Pharma 2008;10:90-93.
4. Chrzanowski FA. The Case for Written Standard Operating Procedures in the Pharmaceutical Development Laboratory: Example - The Preformulation Physical-Pharmacy Laboratory. Pharm Form Qual; 2006;8:58-60.
5. Chrzanowski FA. Conflicts Between SOPs – Resolving Issues in Intramural Corporate and Client/Vendor Procedures. Contract Pharma 2005;7:60-68.